NCT00418795View on ClinicalTrials.gov

Porphozym in the Treatment of Acute Attacks in AIP

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 11, 2003

Primary Completion Date

June 20, 2006

Study Completion Date

June 20, 2006

Conditions
Acute Intermittent Porphyria
Interventions
DRUG

recombinant human porphobilinogen deaminase (Porphozym)

Trial Locations (1)

77555-1109

Univercity Texas Medical Branch, Galveston

All Listed Sponsors
lead

Zymenex A/S

INDUSTRY

NCT00418795 - Porphozym in the Treatment of Acute Attacks in AIP | Biotech Hunter | Biotech Hunter